AIMTo evaluate intra- and interobserver agreement in imaging features in inflammatory bowel disease and comparison with fecal calprotectin (FC) levels.METHODSOur institutional computed tomography enterography (CTE) database was retrospectively queried to identify patients who underwent CTE from January 2014 to June 2015. Patient inclusion criteria were confirmed inflammatory bowel disease (IBD) and FC collected < 4 mo after CTE without any change in clinical treatment or surgical treatment during this interval. The exclusion criterion was poor image quality. Two blinded abdominal radiologists, with 12 and 3 years of experience analyzed the CTE regarding localization (small bowel, colonic, both, or no disease detected); type of IBD (inflammatory, stenosing, fistulizing, > 1 pattern, or normal); and signs of active disease (present or absent). In 42 of 44 patients evaluated, routine CTE reports were made by one of the readers who re-evaluated the CTEs ≥ 6 mo later, to determine the intraobserver agreement. FC was considered a sign of disease activity when it was higher than 250 μg/g.RESULTSForty-four patients with IBD (38 with Crohn’s disease and 6 with ulcerative colitis) were included. There was a moderate interobserver agreement regarding localization of IBD (κ = 0.540), type of disease (κ = 0.410) and the presence of active signs in CTE (κ = 0.419). There was almost perfect intraobserver agreement regarding localization, type and signs of active disease in IBD. The κ values were 0.902, 0.937 and 0.830, respectively. After a consensus between both radiologists regarding inflammatory activity in CTE, we found that 24 (85.7%) of 28 patients who were classified with active disease had elevated FC, and six (37.5%) of 16 patients without inflammatory activity in CTE had elevated FC (P = 0.003). The correlation between elevated FC and the presence of active disease in CTE was significant (κ = 0.495, P = 0.001).CONCLUSIONWe found almost perfect intraobserver and moderate interobserver agreement in the signs of active disease in CTE with concurrence of high FC levels.

Objective: This study aimed to evaluate the Simvastatin pleiotropic effects in coagulation on rats with abdominal sepis. Methods: Twelve Wistar rats (three months, 273-297g) were randomly assigned to abdominal septic group (n=6), induced by cecal ligation and pucture (CLP) and septic group with a previous drug treatment (n=6). The Simvastatin/CLP group was treated with oral simvastatin (10 mg/Kg), eighteen and two hours before the CLP procedure or normal saline solution 0.9%. Peripheral blood laboratory determinations: Platelets, ativated troboplastin parcial time, activated coagulation time, protrombin time, trombin time, fibrinogen dosage, factor VII and factor VIII. Statistical analysis was done by ANOVA and Tukey test, with p<0.05. Results: It wasn't found any significant statistic differences between the groups. Conclusion: Simvastatin did not change the coagulation in rats with abdominal sepsis, according to this experimental model. RESUMOObjetivo: Avaliar o efeito da sinvastatina na coagulação em ratos portadores de sepse de origem abdominal. Métodos: Foram utilizados 12 ratos Wistar, 3 meses de idade, 273-297g. Os animais foram divididos aleatoriamente em: Grupo sepse abdominal, submetidos à ligadura e punção do ceco (LPC), sem receber tratamento medicamentoso prévio e Grupo LPC/Sinvastatina, submetidos à ligadura e punção do ceco, tratados com 10mg/Kg de sinvastatina via oral por sonda de gavagem 18h e 2h antes da ligadura e punção do ceco. Dosagens Laboratoriais: Hemograma; Tempo de Tromboplastina Parcial Ativada (TTPa); Tempo de Protrombina (PT); Effect of simvastatin on coagulation in rats with abdominal sepsis Araújo-Filho, I, et al J Surg Cl Res -Vol. 3 (2) 2012:68-74 69 Contagem e morfologia de plaquetas; Fator VII; Fator VIII. As comparações dos grupos foram realizadas pela análise de variância ANOVA seguido pelo Teste de Turkey. Sendo os resultados considerados estatisticamente significativos quando p<0,05. Resultados: Não foram encontradas diferenças estatisticamente significativas entre os dois grupos. Conclusão: A sinvastatina não alterou a coagulação em ratos portadores de sepse abdominal, de acordo com o modelo experimental usado. Descritores: Sepse. Peritonite. Coagulação. Sinvastatina. Effect of simvastatin on coagulation in rats with abdominal sepsis Araújo-Filho, I, et al J Surg Cl Res -Vol. 3 (2) 2012:68-74 71 Effect of simvastatin on coagulation in rats with abdominal sepsis Araújo-Filho, I, et al J Surg Cl Res -Vol. 3 (2) 2012:68-74 74